Revive Therapeutics Ltd. is a life sciences company focused on the research and development of therapeutics for rare disorders and infectious diseases. Revive aims to advance Psilocybin-based therapeutics in various diseases and disorders and will prioritize development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations.
Stock Performance
Revive Therapeutics News 64 articles
- Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
- Revive Therapeutics Announces Proposed Shares for Debt Transaction
- Revive Therapeutics to Investigate Bucillamine’s Potential in Cancer Treatment
- Revive Therapeutics Announces Acquisition of Molecular Hydrogen Program
- Revive Therapeutics Announces Results of Annual Shareholder Meeting
- Revive Therapeutics Announces LOI to Acquire DiagnaMed’s Molecular Hydrogen Program
- Revive Therapeutics Announces Update on R&D Focus on Bucillamine for Infectious Diseases and Medical Countermeasures
- Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
- Revive Therapeutics Announces Publication Demonstrating Novel Therapeutic Approach of Psilocybin in Stroke
- Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
- Revive Therapeutics Announces Strategic Focus on Bucillamine for Infectious Diseases and Medical Countermeasures
- Revive Therapeutics Provides (Yet Another) Update on Bucillamine for Nerve Agent Exposure
- Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
- Revive Therapeutics Provides Update on FDA Type C Meeting for Clinical Study of Bucillamine to Treat Long COVID
- Revive Therapeutics Provides Update From FDA Meeting for Long COVID Diagnostic Product
- Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
- Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product
- Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID
- Revive Therapeutics Ltd. Announces Closing of the Second and Final Tranche of Its Private Placement for Gross Proceeds of $1,187,110
- Revive Therapeutics Ltd. Announces Closing of the First Tranche of Its Private Placement for Gross Proceeds of $913,500
- Revive Therapeutics Ltd. Announces Offering of Up to $3 Million
- Revive Therapeutics Announces Results of Annual General and Special Meeting of Shareholders
- Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development
- Revive Therapeutics Enters into Worldwide Exclusive Agreement with Lawson Health Research Institute to Develop and Commercialize a Novel Long COVID Rapid Test
- Revive Therapeutics Enters into Agreement with Defence Research and Development Canada for Evaluating Bucillamine for Nerve Agent Exposure
- Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development
- Revive Therapeutics Announces Initiation of Novel Bucillamine Formulation Development
- Revive Therapeutics Announces Filing of Patent for Bucillamine in the Treatment of Exposure to Chemical Warfare Agents
- Revive Therapeutics Announces Results of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
- Revive Therapeutics Announces Data Safety Monitoring Board Meeting Date on Phase 3 Clinical Study of Bucillamine in the Treatment of COVID-19
- Revive Therapeutics Advances MDMA Transdermal Patch Development with Purchase of MDMA Supply from PharmAla Biotech
- Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
- Revive Therapeutics Provides Update From Type C Meeting with FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
- Revive Therapeutics Secures MDMA Supply from PharmAla Biotech for MDMA Transdermal Patch Development
- PharmAla Named Exclusive MDMA Supplier to Revive Therapeutics
- Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development of MDMA Transdermal Patch
- Revive Therapeutics Submits Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
- Revive Therapeutics Ltd. Closes $4.3 Million Offering
- Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
- Revive Therapeutics Ltd. Expands Life Offering to Quebec
Showing the 40 most recent of 64 articles.